Mesenchymal stem cell treatment for hyperactive immune response in patients with COVID-19-Reference-Cited by-同舟云学术

Mesenchymal stem cell treatment for hyperactive immune response in patients with COVID-19

Published:2022-09 Issue:13 Volume:14 Page:1055-1065
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Manoharan Ragul¹,Kore Rajshekhar A²,Mehta Jawahar L²^ORCID

Affiliation:

1. School of Medicine, St George’s University, St George, Grenada, West Indies

2. Division of Cardiology, University of Arkansas for Medical Sciences & The Veterans Affairs Medical Center, Little Rock, AR 72205-5484, USA

Abstract

The human immune system protects the body against invasive organisms and kicks into a hyperactive mode in COVID-19 patients, particularly in those who are critically sick. Therapeutic regimens directed at the hyperactive immune system have been found to be effective in the treatment of patients with COVID-19. An evolving potential treatment option is therapy with mesenchymal stem cells (MSCs) due to their regenerative and reparative ability in epithelial cells. Clinical trials have reported the safe usage of MSC therapy. Systemic effects of MSC treatment have included a reduction in pro-inflammatory cytokines and a decrease in the levels of CRP, IL-6, and lactase dehydrogenase, which function as independent biomarkers for COVID-19 mortality and respiratory failure.

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2021-0245

Reference50 articles.

1. Stem Cell Therapy Potency in Personalizing Severe COVID-19 Treatment

2. How to translate the knowledge of COVID‐19 into the prevention of Omicron variants

3. Lyngse FP, Mortensen LH, Denwood M SARS-CoV-2 Omicron VOC transmission in Danish households. www.medrxiv.org/content/10.1101/2021.12.27.21268278v1

4. COVID ‐19, thromboembolic risk, and Virchow's triad: Lesson from the past

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Combination of Chitosan-Based Biomaterial and Cellular Therapy for Successful Treatment of Diabetic Foot—Pilot Study;International Journal of Molecular Sciences;2024-08-01

2. Understanding host-graft crosstalk for predicting the outcome of stem cell transplantation;World Journal of Stem Cells;2024-03-26

3. Immunosuppressive therapy and COVID‐19 infection in patients with NMOSD;Immunity, Inflammation and Disease;2024-01

4. The Art of Stem Cell-Based Therapy;Potency Assays for Advanced Stem Cell Therapy Medicinal Products;2023